204 related articles for article (PubMed ID: 33406361)
1. CC Chemokine Receptor 2-Targeting Copper Nanoparticles for Positron Emission Tomography-Guided Delivery of Gemcitabine for Pancreatic Ductal Adenocarcinoma.
Zhang X; Detering L; Sultan D; Luehmann H; Li L; Heo GS; Zhang X; Lou L; Grierson PM; Greco S; Ruzinova M; Laforest R; Dehdashti F; Lim KH; Liu Y
ACS Nano; 2021 Jan; 15(1):1186-1198. PubMed ID: 33406361
[TBL] [Abstract][Full Text] [Related]
2. Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma.
Noel M; O'Reilly EM; Wolpin BM; Ryan DP; Bullock AJ; Britten CD; Linehan DC; Belt BA; Gamelin EC; Ganguly B; Yin D; Joh T; Jacobs IA; Taylor CT; Lowery MA
Invest New Drugs; 2020 Jun; 38(3):800-811. PubMed ID: 31297636
[TBL] [Abstract][Full Text] [Related]
3. Treatment and Visualization of Pancreatic Ductal Adenocarcinoma through Actively Targeted Copper 64 Nanoparticles.
MacCuaig WM; McNally LR
Radiol Imaging Cancer; 2021 Mar; 3(2):e219005. PubMed ID: 33817657
[No Abstract] [Full Text] [Related]
4. Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.
Nagathihalli NS; Castellanos JA; Shi C; Beesetty Y; Reyzer ML; Caprioli R; Chen X; Walsh AJ; Skala MC; Moses HL; Merchant NB
Gastroenterology; 2015 Dec; 149(7):1932-1943.e9. PubMed ID: 26255562
[TBL] [Abstract][Full Text] [Related]
5. Self-Assembled Gemcitabine Prodrug Nanoparticles Show Enhanced Efficacy against Patient-Derived Pancreatic Ductal Adenocarcinoma.
Wu L; Zhang F; Chen X; Wan J; Wang Y; Li T; Wang H
ACS Appl Mater Interfaces; 2020 Jan; 12(3):3327-3340. PubMed ID: 31872760
[TBL] [Abstract][Full Text] [Related]
6. Targeting both tumour-associated CXCR2
Nywening TM; Belt BA; Cullinan DR; Panni RZ; Han BJ; Sanford DE; Jacobs RC; Ye J; Patel AA; Gillanders WE; Fields RC; DeNardo DG; Hawkins WG; Goedegebuure P; Linehan DC
Gut; 2018 Jun; 67(6):1112-1123. PubMed ID: 29196437
[TBL] [Abstract][Full Text] [Related]
7. Chemokine Receptor 2 Targeted PET/CT Imaging Distant Metastases in Pancreatic Ductal Adenocarcinoma.
Zhang X; Detering L; Heo GS; Sultan D; Luehmann H; Li L; Somani V; Lesser J; Tao J; Kang LI; Li A; Lahad D; Rho S; Ruzinova MB; DeNardo DG; Dehdashti F; Lim KH; Liu Y
ACS Pharmacol Transl Sci; 2024 Jan; 7(1):285-293. PubMed ID: 38230294
[TBL] [Abstract][Full Text] [Related]
8. EGFR-targeted gelatin nanoparticles for systemic administration of gemcitabine in an orthotopic pancreatic cancer model.
Singh A; Xu J; Mattheolabakis G; Amiji M
Nanomedicine; 2016 Apr; 12(3):589-600. PubMed ID: 26656632
[TBL] [Abstract][Full Text] [Related]
9. Simvastatin attenuates macrophage-mediated gemcitabine resistance of pancreatic ductal adenocarcinoma by regulating the TGF-β1/Gfi-1 axis.
Xian G; Zhao J; Qin C; Zhang Z; Lin Y; Su Z
Cancer Lett; 2017 Jan; 385():65-74. PubMed ID: 27840243
[TBL] [Abstract][Full Text] [Related]
10. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S
Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621
[TBL] [Abstract][Full Text] [Related]
11. Tracking Macrophage Infiltration in a Mouse Model of Pancreatic Cancer with the Positron Emission Tomography Tracer [11C]PBR28.
Lanfranca MP; Lazarus J; Shao X; Nathan H; Di Magliano MP; Zou W; Piert M; Frankel TL
J Surg Res; 2018 Dec; 232():570-577. PubMed ID: 30463776
[TBL] [Abstract][Full Text] [Related]
12. Gemcitabine-loaded microbubble system for ultrasound imaging and therapy.
Delaney LJ; Eisenbrey JR; Brown D; Brody JR; Jimbo M; Oeffinger BE; Stanczak M; Forsberg F; Liu JB; Wheatley MA
Acta Biomater; 2021 Aug; 130():385-394. PubMed ID: 34082100
[TBL] [Abstract][Full Text] [Related]
13. RETSAT associates with DDX39B to promote fork restarting and resistance to gemcitabine based chemotherapy in pancreatic ductal adenocarcinoma.
Tu Q; Liu X; Yao X; Li R; Liu G; Jiang H; Li K; Chen Q; Huang X; Chang Q; Xu G; Zhu H; Shi P; Zhao B
J Exp Clin Cancer Res; 2022 Sep; 41(1):274. PubMed ID: 36109793
[TBL] [Abstract][Full Text] [Related]
14. Two-wave nanotherapy to target the stroma and optimize gemcitabine delivery to a human pancreatic cancer model in mice.
Meng H; Zhao Y; Dong J; Xue M; Lin YS; Ji Z; Mai WX; Zhang H; Chang CH; Brinker CJ; Zink JI; Nel AE
ACS Nano; 2013 Nov; 7(11):10048-65. PubMed ID: 24143858
[TBL] [Abstract][Full Text] [Related]
15. Periostin promotes the chemotherapy resistance to gemcitabine in pancreatic cancer.
Liu Y; Li F; Gao F; Xing L; Qin P; Liang X; Zhang J; Qiao X; Lin L; Zhao Q; Du L
Tumour Biol; 2016 Nov; 37(11):15283-15291. PubMed ID: 27696296
[TBL] [Abstract][Full Text] [Related]
16. Pancreatic adenocarcinoma preferentially takes up and is suppressed by synthetic nanoparticles carrying apolipoprotein A-II and a lipid gemcitabine prodrug in mice.
Smith RC; Bulanadi JC; Gill AJ; Rye KA; Hugh T; Proschogo N; Smith SF; Phillips L; Gong X; Julovi SM; Xue A; Moghaddam MJ
Cancer Lett; 2020 Dec; 495():112-122. PubMed ID: 32949679
[TBL] [Abstract][Full Text] [Related]
17. Gemcitabine enhances the transport of nanovector-albumin-bound paclitaxel in gemcitabine-resistant pancreatic ductal adenocarcinoma.
Borsoi C; Leonard F; Lee Y; Zaid M; Elganainy D; Alexander JF; Kai M; Liu YT; Kang Y; Liu X; Koay EJ; Ferrari M; Godin B; Yokoi K
Cancer Lett; 2017 Sep; 403():296-304. PubMed ID: 28687352
[TBL] [Abstract][Full Text] [Related]
18. Nano-delivery of Gemcitabine Derivative as a Therapeutic Strategy in a Desmoplastic KRAS Mutant Pancreatic Cancer.
Das M; Li J; Bao M; Huang L
AAPS J; 2020 Jun; 22(4):88. PubMed ID: 32572645
[TBL] [Abstract][Full Text] [Related]
19. Inhibiting tumor necrosis factor-alpha diminishes desmoplasia and inflammation to overcome chemoresistance in pancreatic ductal adenocarcinoma.
Zhao X; Fan W; Xu Z; Chen H; He Y; Yang G; Yang G; Hu H; Tang S; Wang P; Zhang Z; Xu P; Yu M
Oncotarget; 2016 Dec; 7(49):81110-81122. PubMed ID: 27835602
[TBL] [Abstract][Full Text] [Related]
20. TGF-β-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3.
Hesler RA; Huang JJ; Starr MD; Treboschi VM; Bernanke AG; Nixon AB; McCall SJ; White RR; Blobe GC
Carcinogenesis; 2016 Nov; 37(11):1041-1051. PubMed ID: 27604902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
